December 9, 2024 11:15 AM EST
R&D
Pharma

Ab­b­Vie de­clares third Phase 3 Parkin­son’s win from Cerev­el takeover

Ayisha Sharma

News Reporter

There’s a sil­ver lin­ing for Ab­b­Vie on its close­ly-fol­lowed buy­out of Cerev­el: The phar­ma com­pa­ny re­port­ed Mon­day that its Parkin­son’s dis­ease can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times